Radiopharma Goes Supercritical: Telix Pays Up to $2.35bn for ITM Weeks After an FDA Setback
bIAnk AI Research · September 2026 · 7 min
Telix agreed on 21 September 2026 to buy ITM Isotope Technologies Munich for $1.65bn upfront and up to $2.35bn including milestones — the same day Grünenthal bought Bayer's Stivarga and days after GE HealthCare was reported in talks for Sofie Biosciences. Buyers are paying for isotope supply and manufacturing scale, not for approved labels.
The headline terms: $1.65bn upfront on a cash-free, debt-free basis, of which roughly $1.25bn is payable in Telix shares priced at $11.84, plus contingent consideration of up to $700m linked to ITM-11 regulatory and commercial milestones — a total of up to $2.35bn. Telix also assumes more than $300m of ITM debt at closing. Post-completion, Telix shareholders hold about 76.3% and ITM backers about 23.7%, with the combined business projecting more than $1.3bn of unaudited revenue this year. Closing is targeted for end-2026 subject to Telix shareholder approval.
What makes the price notable is its timing. ITM's lead asset, ITM-11 (177Lu-edotreotide), received an FDA Complete Response Letter over manufacturing concerns only weeks before signing. A buyer paying a premium immediately after a CRL is not buying the label; it is buying the isotope supply chain, the GMP manufacturing base and a revenue line that has compounded at roughly 40% a year since 2021 to $273m.
The sector context reinforces that reading. On the same day, Grünenthal agreed to acquire Bayer's oncology drug Stivarga (regorafenib) for up to €375m, continuing a programme that has deployed roughly €2.6bn on M&A since 2017. On 13 September, GE HealthCare was reported to be in talks over a roughly $1bn acquisition of radiopharma company Sofie Biosciences.
Radiopharmaceuticals are structurally supply-constrained: the isotopes decay, so production must sit close to the patient and capacity cannot be imported at short notice. That converts manufacturing capability into a strategic scarcity asset, and scarcity assets trade on control premia rather than on discounted product cash flows. It is why a manufacturing-related regulatory letter reduced the risk-adjusted value of one programme without materially reducing the value of the platform.
For founders and investors in specialised industrial or life-science assets, the lesson generalises. When the scarce input is capacity rather than intellectual property, valuation should be anchored on replacement cost and time-to-build, not on a DCF of the current product pipeline. Framing the equity story that way — with documented capacity, qualifications and lead times — is typically worth more in a negotiation than another quarter of clinical newsflow.
Key takeaways
- Telix / ITM (21 Sept 2026): $1.65bn upfront, up to $2.35bn with $700m of milestones, plus >$300m of assumed debt
- Consideration mostly in stock: ~$1.25bn in Telix shares at $11.84; post-deal split 76.3% / 23.7%
- ITM revenue compounded ~40% a year since 2021 to $273m, despite an FDA CRL on ITM-11 weeks before signing
- Same-week comparables: Grünenthal / Bayer Stivarga (up to €375m) and GE HealthCare in talks for Sofie Biosciences (~$1bn)